Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan plus Pembrolizumab vs Placebo plus Pembrolizumab in Adjuvant ccRCC
NCT05239728Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of belzutifan in clear cell renal cell carcinoma (ccRCC), sponsored by Merck & Co.. Started Mar 2022; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05239728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239728.